129 related articles for article (PubMed ID: 32664334)
21. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
[TBL] [Abstract][Full Text] [Related]
22. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms.
Jensen PØ; Briales A; Brochmann RP; Wang H; Kragh KN; Kolpen M; Hempel C; Bjarnsholt T; Høiby N; Ciofu O
Pathog Dis; 2014 Apr; 70(3):440-3. PubMed ID: 24376174
[TBL] [Abstract][Full Text] [Related]
23. Induction of bacteria in biofilm into a VBNC state by chlorine and monitoring of biofilm structure changes by means of OCT.
Guo L; Ye C; Yu X; Horn H
Sci Total Environ; 2023 Sep; 891():164294. PubMed ID: 37236444
[TBL] [Abstract][Full Text] [Related]
24. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.
Beaudoin T; Stone TA; Glibowicka M; Adams C; Yau Y; Ahmadi S; Bear CE; Grasemann H; Waters V; Deber CM
Sci Rep; 2018 Oct; 8(1):14728. PubMed ID: 30283025
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
[No Abstract] [Full Text] [Related]
26. Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms.
Ahmed MN; Porse A; Abdelsamad A; Sommer M; Høiby N; Ciofu O
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31307984
[TBL] [Abstract][Full Text] [Related]
27. High throughput determination of the biofilm prevention concentration for
De Bleeckere A; Van den Bossche S; De Sutter PJ; Beirens T; Crabbé A; Coenye T
Biofilm; 2023 Dec; 5():100106. PubMed ID: 36845825
[TBL] [Abstract][Full Text] [Related]
28. Marine-derived quorum-sensing inhibitory activities enhance the antibacterial efficacy of tobramycin against Pseudomonas aeruginosa.
Busetti A; Shaw G; Megaw J; Gorman SP; Maggs CA; Gilmore BF
Mar Drugs; 2014 Dec; 13(1):1-28. PubMed ID: 25546516
[TBL] [Abstract][Full Text] [Related]
29. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
[TBL] [Abstract][Full Text] [Related]
30. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
[TBL] [Abstract][Full Text] [Related]
31. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
32. Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Kirov SM; Webb JS; O'May CY; Reid DW; Woo JKK; Rice SA; Kjelleberg S
Microbiology (Reading); 2007 Oct; 153(Pt 10):3264-3274. PubMed ID: 17906126
[TBL] [Abstract][Full Text] [Related]
33. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
34. Propidium monoazide-quantitative polymerase chain reaction (PMA-qPCR) assay for rapid detection of viable and viable but non-culturable (VBNC)
Golpayegani A; Douraghi M; Rezaei F; Alimohammadi M; Nodehi RN
J Environ Health Sci Eng; 2019 Jun; 17(1):407-416. PubMed ID: 31297217
[TBL] [Abstract][Full Text] [Related]
35. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Sousa AM; Monteiro R; Pereira MO
Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
[TBL] [Abstract][Full Text] [Related]
36. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
Moriarty TF; Elborn JS; Tunney MM
Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
[TBL] [Abstract][Full Text] [Related]
39. Microbiological and immunologic considerations with aerosolized drug delivery.
LiPuma JJ
Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
